A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Percentage of Participants Achieving Clinical Response at Week 14 [Time Frame: Up to Week 14]

Percentage of Participants Achieving Clinical Remission at Week 14 [Time Frame: Up to Week 14]

Percentage of Participants Achieving Endoscopic Response at Week 14 [Time Frame: Up to Week 14]

Percentage of Participants Achieving Both Clinical Response and Endoscopic Response at Week 14 [Time Frame: Up to Week 14]

Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Discontinuation [Time Frame: From first dose up to 18 weeks after the final dose of vedolizumab (Up to approximately 78 weeks)]

Percentage of Participants With Abnormal Change from Baseline in Vital Sign Values [Time Frame: From first dose up to 18 weeks after the final dose of vedolizumab (Up to approximately 78 weeks)]

Percentage of Participants With Abnormal Change from Baseline in Laboratory Values [Time Frame: From first dose up to 18 weeks after the final dose of vedolizumab (Up to approximately 78 weeks)]

Percentage of Participants With Abnormal Change from Baseline in Electrocardiogram (ECG) Values [Time Frame: From first dose up to 18 weeks after the final dose of vedolizumab (Up to approximately 78 weeks)]